biotech3.19 min read
AI uncovers the data behind Novo's Parkinson's stem-cell program
1 day ago•Source: Endpoints News
Biotech News
The latest biotech stories, summarized by AI
Featured Biotech Stories
View original source
3.21 min•1 day ago
US Biotech Firms Go Quiet as China Emerges as a Rival
As Chinese biotech competition intensifies, US drugmakers are increasingly secretive and cautious about intellectual property and development strategies, fueling a shift toward more guarded operations in areas like AI-driven drug discovery and next-gen therapies.
More Top Stories
2
MeiraGTx lands up to $400M to accelerate commercialization of late-stage gene therapies
Fierce Biotech•3 days ago
3
More Biotech Stories
Scribe Therapeutics files for Nasdaq IPO to test appetite for early-stage biotech
Scribe Therapeutics filed for a Nasdaq IPO to gauge investor appetite for early-stage biotech and gene-editing startups, backed by major investors including RA Capital, Andreessen Horowitz, OrbiMed and Avoro Capital.
KRAS combo data prompts Revolution Medicines toward Phase 3
Revolution Medicines revealed early data for a two-KRAS inhibitor drug combination, including Daraxonrasib, and plans a Phase 3 trial, signaling potential progress in targeting KRAS-driven cancers.
Moderna Co‑Founder Bets Big on mRNA’s Cancer-Vaccine Promise
Moderna co-founder Kenneth Chien remains bullish on mRNA’s potential, predicting an mRNA cancer vaccine could reshape oncology and lift the entire field, even as past Moderna–AstraZeneca deals failed to deliver the planned drugs.
China-based cancer-therapy timing study retracted, fueling anti-China lobbying
Nature Medicine has retracted a high-profile February paper detailing the results of a China-based trial on the timing of cancer therapy, a move that could energize anti-China policymakers and influence debates around immunotherapy timing.
Lilly grants single-patient compassionate-use access to retatrutide
Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.
GSK to buy Nuvalent for $10.6B, snagging two experimental lung-cancer drugs
GSK plans a $10.6 billion acquisition of Nuvalent to gain two experimental lung-cancer medicines (Zidesamtinib and Neladalkib) currently under FDA review, bolstering its oncology pipeline amid a major biotech deal.
Lilly China deals, Akeso bispecific advance, ASCO updates reshape biotech
The Readout highlights Eli Lilly’s two China deals, Akeso’s promising lung cancer bispecific, and ASCO-driven updates on pancreatic cancer therapies (including daraxonrasib results), alongside chatter about a high-profile Chinese lung cancer therapy and a broader regulatory debate over an old peptide, illustrating how deals, trials, and policy are shaping biotech today.
Lilly’s one-dose gene editor cuts LDL by 62% in early trial
Eli Lilly’s high-dose, one-time gene-editing therapy VERVE-102 lowered LDL cholesterol by 62% in a Phase 1 trial, with no treatment-related serious adverse events, signaling potential for a single-shot approach to prevent heart disease after Lilly’s $1 billion acquisition of Verve Therapeutics.
Bacteria-Inspired Peptide Disrupts Cancer Energy, Enhances Radiation Therapy
AurB, a bacteria-derived peptide, enters tumor cell mitochondria and blocks ATP production, starving cancer cells; in preclinical prostate cancer models, its activity is strongest when combined with radiation, slowing tumor growth and prompting plans for clinical trials.
Erasca’s RAS-targeted pill shows early tumor shrinkage in pancreatic and lung cancer trials
Erasca reported preliminary data showing its RAS-targeting pill ERAS-0015 shrank tumors in 40% of advanced pancreatic cancer patients and 62% of advanced non-small cell lung cancer patients from studies in the U.S. and China, suggesting potential advantages over a rival drug from Revolution Medicines. While the data are early and the lung results appear more definitive, Erasca says the clinical benefit and tolerability are promising and that all strategic options remain under consideration.